Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Unlike the investment banks, we created StockStory to provide independent analysis that helps you determine which companies are truly worth following. Keeping that in mind, here are two stocks where Wall Street’s positive outlook is supported by strong fundamentals and one where analysts may be overlooking some important risks.
One Stock to Sell:
Addus HomeCare (ADUS)
Consensus Price Target: $136.45 (26.5% implied return)
Serving approximately 66,000 clients across 22 states with a focus on "dual eligible" Medicare and Medicaid beneficiaries, Addus HomeCare (NASDAQ: ADUS) provides in-home personal care, hospice, and home health services to elderly, chronically ill, and disabled individuals.
Why Is ADUS Not Exciting?
- Modest revenue base of $1.21 billion gives it less fixed cost leverage and fewer distribution channels than larger companies
At $107.88 per share, Addus HomeCare trades at 17.4x forward P/E. If you’re considering ADUS for your portfolio, see our FREE research report to learn more.
Two Stocks to Watch:
Tenet Healthcare (THC)
Consensus Price Target: $196.81 (23.4% implied return)
With a network spanning nine states and serving primarily urban and suburban communities, Tenet Healthcare (NYSE: THC) operates a nationwide network of hospitals, ambulatory surgery centers, and outpatient facilities providing acute care and specialty healthcare services.
Why Could THC Be a Winner?
- Share repurchases have amplified shareholder returns as its annual earnings per share growth of 29.1% exceeded its revenue gains over the last five years
- Stellar returns on capital showcase management’s ability to surface highly profitable business ventures, and its returns are growing as it capitalizes on even better market opportunities
- Improving returns on capital reflect management’s ability to monetize investments
Tenet Healthcare’s stock price of $159.50 implies a valuation ratio of 12.4x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Integral Ad Science (IAS)
Consensus Price Target: $13.46 (65.4% implied return)
Founded in 2009, Integral Ad Science (NASDAQ: IAS) provides digital advertising verification and optimization solutions, ensuring that ads are viewable by real people in brand-safe environments across various platforms and devices.
Why Are We Fans of IAS?
- Well-designed software integrates seamlessly with other workflows, enabling swift payback periods on marketing expenses and customer growth at scale
- Operating margin expanded by 11.3 percentage points over the last year as it scaled and became more efficient
- Robust free cash flow margin of 22.1% gives it many options for capital deployment
Integral Ad Science is trading at $8.14 per share, or 2.2x forward price-to-sales. Is now the time to initiate a position? See for yourself in our comprehensive research report, it’s free.
High-Quality Stocks for All Market Conditions
When Trump unveiled his aggressive tariff plan in April 2024, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.
Don’t let fear keep you from great opportunities and take a look at Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
